title: (131)I treatment in Differentiated Thyroid Cancer and End-Stage Renal Disease.
abstract: OBJECTIVE
  Radioiodine (RAI) is a cornerstone in the treatment of Differentiated Thyroid Cancer (DTC). In patients on haemodialysis due to End-Stage Renal Disease (ESRD), it must be used cautiously, considering the renal clearance of this radionuclide. Also, the safety of the procedure and subsequent long-term outcome is still not well defined. In 2001, we described a dosimetric method and short-term results in three patients, with a good safety profile. We hypothesize that our method is safe in a long-term scenario without compromising the prognosis of both renal and thyroid disease.
  
  
  METHODS
  Descriptive-retrospective study. A systematic search was carried out using our clinical database from 2000 to 2014.
  
  
  METHODS
  DTC and radioiodine treatment while on haemodialysis.
  
  
  METHODS
  peritoneal dialysis.
  
  
  RESULTS
  Final sample n=9 patients (n=5 males), age 48 years (median age 51 years males, 67 years female group); n=8 papillary thyroid cancer, n=1 follicular thyroid cancer; n=5 lymph node invasion; n=1 metastatic disease. Median RAI dose administered on haemodialysis 100mCi. 7.5 years after radioiodine treatment on haemodialysis, n=7 deemed free of thyroid disease, n=1 persistent non-localised disease. No complications related to the procedure or other target organs were registered. After 3.25 years, n=4 patients underwent successful renal transplantation; n=4 patients did not meet transplantation criteria due to other conditions unrelated to the thyroid disease or its treatment. One patient died due to ischemic cardiomyopathy (free of thyroid disease).
  
  
  CONCLUSIONS
  Radioiodine treatment during haemodialysis is a long-term, safe procedure without worsening prognosis of either renal or thyroid disease.
authors.affiliation: Unidad de Gestión Clínica de Endocrinología y nutrición, Hospital Universitario Virgen del Rocío, Instituto de Biomedicina de Sevilla (IBiS), Avenida Manuel Siurot s/n, CP 41013 Sevilla, Spain.
authors.forename: A J M
authors.initials: AJ
authors.lastname: Ortega
authors.affiliation: Unidad de Gestión Clínica de Endocrinología y nutrición, Hospital Universitario Virgen del Rocío, Instituto de Biomedicina de Sevilla (IBiS), Avenida Manuel Siurot s/n, CP 41013 Sevilla, Spain.
authors.forename: R G
authors.initials: RG
authors.lastname: Vázquez
authors.affiliation: Unidad de Medicina Nuclear y Radiofísica, Hospital Universitario Virgen del Rocío, Instituto de Biomedicina de Sevilla (IBiS), Avenida Manuel Siurot s/n, CP 41013 Sevilla, Spain.
authors.forename: J I C
authors.initials: JI
authors.lastname: Cuenca
authors.affiliation: Unidad de Gestión Clínica de Endocrinología y nutrición, Hospital Universitario Virgen del Rocío, Instituto de Biomedicina de Sevilla (IBiS), Avenida Manuel Siurot s/n, CP 41013 Sevilla, Spain.
authors.forename: M A M
authors.initials: MA
authors.lastname: Brocca
authors.affiliation: Unidad de UroNefrología, Hospital Universitario Virgen del Rocío, Instituto de Biomedicina de Sevilla (IBiS), Avenida Manuel Siurot s/n, CP 41013 Sevilla, Spain.
authors.forename: J
authors.initials: J
authors.lastname: Castilla
authors.affiliation: Unidad de Cirugía Endocrinológica, Hospital Universitario Virgen del Rocío, Instituto de Biomedicina de Sevilla (IBiS), Avenida Manuel Siurot s/n, CP 41013 Sevilla, Spain.
authors.forename: J M M
authors.initials: JM
authors.lastname: Martínez
authors.affiliation: Unidad de Gestión Clínica de Endocrinología y nutrición, Hospital Universitario Virgen del Rocío, Instituto de Biomedicina de Sevilla (IBiS), Avenida Manuel Siurot s/n, CP 41013 Sevilla, Spain. Electronic address: elena.navarro.sspa@juntadeandalucia.es.
authors.forename: E N
authors.initials: EN
authors.lastname: González
mesh_terms: D018263:Adenocarcinoma, Follicular / Q000150:complications / Q000378:metabolism / Q000532:radiotherapy; D000328:Adult; D000368:Aged; D002277:Carcinoma; D002291:Carcinoma, Papillary / Q000150:complications / Q000378:metabolism / Q000532:radiotherapy*; D005260:Female; D006801:Humans; D007457:Iodine Radioisotopes / Q000009:adverse effects / Q000493:pharmacokinetics / Q000627:therapeutic use*; D007676:Kidney Failure, Chronic / Q000150:complications / Q000378:metabolism* / Q000628:therapy; D016030:Kidney Transplantation; D008297:Male; D008875:Middle Aged; D011379:Prognosis; D019275:Radiopharmaceuticals / Q000009:adverse effects / Q000493:pharmacokinetics / Q000627:therapeutic use*; D006435:Renal Dialysis; D012189:Retrospective Studies; D000077273:Thyroid Cancer, Papillary; D013964:Thyroid Neoplasms / Q000150:complications / Q000378:metabolism / Q000532:radiotherapy*; D016896:Treatment Outcome
chemical_list: D007457:Iodine Radioisotopes; D019275:Radiopharmaceuticals
keywords: Carcinoma tiroideo; End-stage renal disease; Haemodialysis; Hemodiálisis; Insuficiencia renal terminal; Kidney transplantation; Radioiodine; Radioyodo; Thyroid cancer; Trasplante renal